RegulatoryCompany release

iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response

🇺🇸 Insight Molecular Diagnostics Inc. (IMDX) · Mon 16 Nov 2026

Insight Molecular Diagnostics says it will answer the FDA's request for more clinical validation information on its donor-derived cfDNA kit before the 21 January 2027 deadline.

Insight Molecular Diagnostics (iMDx) reported its third-quarter 2026 results on 16 November, with the status of its US regulatory submission for GraftAssureDx a central point. The company's headline revenue figure for the quarter was $559,000.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Insight Molecular Diagnostics Inc. ↗

Article written by VigiEye from the official source (Insight Molecular Diagnostics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →